Skip to main content
SpringerLink
Log in
Book cover

Encyclopedia of Signaling Molecules pp 5592–5600Cite as

TRAIL Receptor 1/2 (Death Receptor 4/5, DR4/5)

  • Reference work entry
  • First Online:

  • 111 Accesses

Synonyms

TRAIL-R1 (tumor necrosis factor-related apoptosis-inducing ligand receptor 1); TRAIL-R2 (tumor necrosis factor-related apoptosis-inducing ligand receptor 2)

Historical Background

The tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL, Apo2L) identified in the middle of 1990s (Pitti et al. 1996; Wiley et al. 1995) was given its name due to its ability of inducing apoptosis and its high homology to other TNF member ligands. Then, its first receptor, death receptor 4 (DR4, TRAIL-R1), was identified by searching an EST database for sequences related to the TNF receptor-1 (TNFR1) death domain (DD) (Pan et al. 1997b). Thereafter, by virtue of its sequence homology to the DR4 DD, death receptor 5 (DR5, TRAIL-R2) was also cloned independently by two groups (MacFarlane et al. 1997; Walczak et al. 1997). Both DR4 and DR5 are belonging to members of the TNF receptor superfamily (TNFRSF). However, unlikely with TNFRSF receptors containing the intracellular DD, such as...

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   4,499.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   4,499.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 2008;7(12):1001.

    Article  PubMed  CAS  Google Scholar 

  • Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155–62.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Cha SS, Sung BJ, Kim YA, Song YL, Kim HJ, Kim S, et al. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem. 2000;275:31171–7.

    Article  PubMed  CAS  Google Scholar 

  • Chen C, Liu Y, Zheng D. An agonistic monoclonal antibody against DR5 induces ROS production, sustained JNK activation and Endo G release in Jurkat leukemia cells. Cell Res. 2009;19:984–95.

    Article  PubMed  CAS  Google Scholar 

  • Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363–7.

    Article  PubMed  CAS  Google Scholar 

  • Fox NL, Humphreys R, Luster TA, Klein J, Gallant G. Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy. Expert Opin Biol Ther. 2010;10:1–18.

    Article  PubMed  CAS  Google Scholar 

  • Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 2010;29:4752–65.

    Article  PubMed  CAS  Google Scholar 

  • Jin Z, El-Deiry WS. Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol. 2006;26:8136–48.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008;8:782–98.

    Article  PubMed  CAS  Google Scholar 

  • Lee CH, Park KJ, Sung ES, Kim A, Choi JD, Kim JS, et al. Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo. Proc Natl Acad Sci U S A. 2010;107:9567–71.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S, et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol. 2000;20:6638–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem. 1997;272:25417–20.

    Article  PubMed  CAS  Google Scholar 

  • MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 2005;65:11265–70.

    Article  PubMed  CAS  Google Scholar 

  • Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol. 1997;7:1003–6.

    Article  PubMed  CAS  Google Scholar 

  • Mills KR, Reginato M, Debnath J, Queenan B, Brugge JS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc Natl Acad Sci U S A. 2004;101:3438–43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Muhlenbeck F, Schneider P, Bodmer JL, Schwenzer R, Hauser A, Schubert G, et al. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem. 2000;275:32208–13.

    Article  PubMed  CAS  Google Scholar 

  • Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997a;277:815–8.

    Article  PubMed  CAS  Google Scholar 

  • Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science. 1997b;276:111–3.

    Article  PubMed  CAS  Google Scholar 

  • Park KJ, Lee SH, Kim TI, Lee HW, Lee CH, Kim EH, et al. A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells. Cancer Res. 2007;67:7327–34.

    Article  PubMed  CAS  Google Scholar 

  • Park KJ, Lee SH, Lee CH, Jang JY, Chung J, Kwon MH, et al. Upregulation of Beclin-1 expression and phosphorylation of Bcl-2 and p53 are involved in the JNK-mediated autophagic cell death. Biochem Biophys Res Commun. 2009;382:726–9.

    Article  PubMed  CAS  Google Scholar 

  • Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, et al. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res. 2010;70:1101–10.

    Article  PubMed  CAS  Google Scholar 

  • Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, de Jong S. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta. 2010;1805:123–40.

    PubMed  CAS  Google Scholar 

  • Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687–90.

    Article  PubMed  CAS  Google Scholar 

  • Sah NK, Munshi A, Kurland JF, McDonnell TJ, Su B, Meyn RE. Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem. 2003;278:20593–602.

    Article  PubMed  CAS  Google Scholar 

  • Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol. 1997;7:693–6.

    Article  PubMed  CAS  Google Scholar 

  • Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation. 2003;107:2250–6.

    Article  PubMed  Google Scholar 

  • Sung ES, Park KJ, Lee SH, Jang YS, Park SK, Park YH, et al. A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Mol Cancer Ther. 2009;8:2276–85.

    Article  PubMed  CAS  Google Scholar 

  • Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem. 2005;280:40599–608.

    Article  PubMed  CAS  Google Scholar 

  • Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997;16:5386–97.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–82.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Science and Technology, Ajou University, San5, Wonchon-Dong, Yeongtong-Gu, Suwon, 443-749, Korea

    Eun-Sil Sung & Yong-Sung Kim

Authors
  1. Eun-Sil Sung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong-Sung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eun-Sil Sung .

Editor information

Editors and Affiliations

  1. Department of Molecular Science and Technology, Ajou University, Suwon, Korea

    Sangdun Choi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Sung, ES., Kim, YS. (2018). TRAIL Receptor 1/2 (Death Receptor 4/5, DR4/5). In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, Cham. https://doi.org/10.1007/978-3-319-67199-4_544

Download citation

Publish with us

Policies and ethics

Search

Navigation